

Special Issue

Cytoreductive Surgery Treatment: Advances and Obstacles

Message from the Guest Editors

Peritoneal dissemination of intra-abdominal malignancies is generally regarded as an unfavorable prognostic indicator. Historically, therapeutic interventions in cases of peritoneal carcinomatosis (PC) were minimal. However, the introduction of cytoreductive surgery (CRS) allowed the macroscopic removal of the peritoneal metastatic foci, while in parallel, the administration of intraperitoneal hyperthermic chemotherapy (HIPEC) enabled the management of the microscopic residual disease, thus improving the survival and quality of life outcomes. The perioperative safety and oncological efficacy of CRS and HIPEC have been confirmed by multiple trials, in various clinical settings. Despite the wide acceptance of CRS, there is still a considerable discrepancy in terms of operative indications, surgical techniques and treatment protocols. We are pleased to invite you to the “Cytoreductive Surgery Treatment: Advances and Obstacles” Special Issue of *Current Oncology*. For further reading, please, visit the [Special Issue](#) website.

Guest Editors

Dr. Konstantinos Perivoliotis
Department of Surgery, General Hospital of Volos, Volos, Greece

Prof. Dr. Konstantinos Tepetes
Department of Surgery, University Hospital of Larissa, Mezourlo, Greece

Deadline for manuscript submissions

closed (31 October 2023)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 3.3
Indexed in PubMed



mdpi.com/si/136147

Current Oncology
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 3.3
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
 2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
-

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility

: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)